


# EGFR polyclonal antibody

Catalog # PAB10223

Size 250 uL

## Applications

### Western Blot (Cell lysate)



Western blot using EGFR polyclonal antibody (Cat # PAB10223) shows detection of a band at ~170 KDa corresponding to human EGFR present in unstimulated (Lane 1) and EGF (50 ng/mL for 15 min) stimulated (Lane 2) A-431 whole cell lysates (arrowhead).

Approximately 30 ug of lysate was resolved on a 4-20% Tris-Glycine gel by SDS-PAGE and transferred onto nitrocellulose.


After blocking, the membrane was probed with the primary antibody diluted to 1:1,000.

Reaction occurred overnight at 4°C followed by washes and reaction with a 1:10,000 dilution of IRDye® 800 conjugated Gt-a-Rabbit IgG (H&L) MX10 for 45 min at room temperature (800 nm channel, green).

Molecular weight estimation was made by comparison to prestained MW markers in lane M (700 nm channel, red).

IRDye® 800 fluorescence image was captured using the Odyssey® Infrared Imaging System developed by LI-COR.

IRDye is a trademark of LI-COR, Inc.



### Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)

Immunohistochemical staining with EGFR polyclonal antibody (Cat # PAB10223) was diluted to 2.5 ug/mL detect EGFR in human ovarian cancer tissue. Tissue was formalin fixed and paraffin embedded. No pre-treatment of sample was required. The image shows the localization of antibody as the precipitated red signal, with a hematoxylin purple nuclear counter stain.

## Immunoprecipitation

Combined immunoprecipitation and immunoblot using EGFR polyclonal antibody (Cat # PAB10223).


Lysates were prepared from GN4 rat liver epithelial cells both with (+) EGF treatment for 15' at 100 ng/mL and without (-) the addition of EGF.

The combination of immunoprecipitation and immunoblotting was performed using the EGFR polyclonal antibody (Cat # PAB10223) for immunoprecipitation (10 uL) followed by immunoblot detection using an anti-phosphotyrosine antibody (Panel A).

This was repeated in reverse order using a 1:2000 dilution of EGFR polyclonal antibody for immunoblot (Panel B).

Visualization occurred using an ECL system.

Film exposure was approximately 1'.



## Specification

<b>Product Description</b>	Rabbit polyclonal antibody raised against synthetic peptide of EGFR.
<b>Immunogen</b>	A synthetic peptide corresponding to C-terminus of human EGFR.
<b>Host</b>	Rabbit
<b>Reactivity</b>	Human, Mouse, Rat
<b>Form</b>	Liquid
<b>Quality Control Testing</b>	Antibody Reactive Against Synthetic Peptide.
<b>Recommend Usage</b>	ELISA (1:10000-1:50000) Western Blot (1:1000-1:10000) Immunoprecipitation (10 ul) The optimal working dilution should be determined by the end user.
<b>Storage Buffer</b>	In antiserum (0.01% sodium azide)
<b>Storage Instruction</b>	Store at 4°C. For long term storage store at -20°C. Aliquot to avoid repeated freezing and thawing.
<b>Note</b>	This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

## Applications

- Western Blot (Cell lysate)

Western blot using EGFR polyclonal antibody (Cat # PAB10223) shows detection of a band at ~170 KDa corresponding to human EGFR present in unstimulated (Lane 1) and EGF (50 ng/mL for 15 min) stimulated (Lane 2) A-431 whole cell lysates (arrowhead).

Approximately 30 ug of lysate was resolved on a 4-20% Tris-Glycine gel by SDS-PAGE and transferred onto nitrocellulose. After blocking, the membrane was probed with the primary antibody diluted to 1:1,000.

Reaction occurred overnight at 4°C followed by washes and reaction with a 1:10,000 dilution of IRDye® 800 conjugated Gt-a-Rabbit IgG (H&L) MX10 for 45 min at room temperature (800 nm channel, green).

Molecular weight estimation was made by comparison to prestained MW markers in lane M (700 nm channel, red).

IRDye® 800 fluorescence image was captured using the Odyssey® Infrared Imaging System developed by LI-COR.

IRDye is a trademark of LI-COR, Inc.

- Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)

Immunohistochemical staining with EGFR polyclonal antibody (Cat # PAB10223) was diluted to 2.5 ug/mL detect EGFR in human ovarian cancer tissue. Tissue was formalin fixed and paraffin embedded. No pre-treatment of sample was required. The image shows the localization of antibody as the precipitated red signal, with a hematoxylin purple nuclear counter stain.

- Immunoprecipitation

Combined immunoprecipitation and immunoblot using EGFR polyclonal antibody (Cat # PAB10223).

Lysates were prepared from GN4 rat liver epithelial cells both with (+) EGF treatment for 15' at 100 ng/mL and without (-) the addition of EGF.

The combination of immunoprecipitation and immunoblotting was performed using the EGFR polyclonal antibody (Cat # PAB10223) for immunoprecipitation (10 uL) followed by immunoblot detection using an anti-phosphotyrosine antibody (Panel A).

This was repeated in reverse order using a 1:2000 dilution of EGFR polyclonal antibody for immunoblot (Panel B).

Visualization occurred using an ECL system.

Film exposure was approximately 1'.

- Enzyme-linked Immunoabsorbent Assay

## Gene Info — EGFR

Entrez GeneID	<a href="#">1956</a>
Protein Accession#	<a href="#">P00533;NP_005219</a>
Gene Name	EGFR
Gene Alias	ERBB, ERBB1, HER1, PIG61, mENA
Gene Description	epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian )
Omim ID	<a href="#">131550 211980</a>

**Gene Ontology**[Hyperlink](#)**Gene Summary**

The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. [provided by RefSeq]

**Other Designations**

avian erythroblastic leukemia viral (v-erb-b) oncogene homolog|cell growth inhibiting protein 40|ce II proliferation-inducing protein 61|epidermal growth factor receptor

## Publication Reference

- [The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development.](#)

Sibilia M, Fleischmann A, Behrens A, Stingl L, Carroll J, Watt FM, Schlessinger J, Wagner EF.

Cell 2000 Jul; 102(2):211.

Application: WB-Ce, Mouse, Keratinocytes

- [Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells.](#)

Sartor CI, Dziubinski ML, Yu CL, Jove R, Ethier SP.

Cancer Research 1997 Mar; 57(5):978.

Application: WB-Ce, Human, SUM-102PT cells

- [Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study.](#)

Henzen-Logmans SC, van der Burg ME, Foekens JA, Berns PM, Brussee R, Fieret JH, Klijn JG, Chadha S, Rodenburg CJ.

Journal of Cancer Research and Clinical Oncology 1992 Apr; 118(4):303.

Application: IHC, Human, Ovarian

## Pathway

- [Adherens junction](#)
- [Bladder cancer](#)
- [Calcium signaling pathway](#)
- [Colorectal cancer](#)
- [Cytokine-cytokine receptor interaction](#)

- [Dorso-ventral axis formation](#)
- [Endocytosis](#)
- [Endometrial cancer](#)
- [Epithelial cell signaling in Helicobacter pylori infection](#)
- [ErbB signaling pathway](#)
- [Focal adhesion](#)
- [Gap junction](#)
- [Glioma](#)
- [GnRH signaling pathway](#)
- [MAPK signaling pathway](#)
- [Melanoma](#)
- [Non-small cell lung cancer](#)
- [Pancreatic cancer](#)
- [Pathways in cancer](#)
- [Prostate cancer](#)
- [Regulation of actin cytoskeleton](#)

## Disease

- [Adenocarcinoma](#)
- [Anus Neoplasms](#)
- [Asthma](#)
- [Astrocytoma](#)
- [Atherosclerosis](#)
- [Barrett Esophagus](#)
- [Bile Duct Neoplasms](#)
- [Biliary Tract Neoplasms](#)

- [Bipolar Disorder](#)
- [Brain Neoplasms](#)
- [Breast cancer](#)
- [Breast Neoplasms](#)
- [Bronchial Hyperreactivity](#)
- [Carcinoma](#)
- [Cardiomyopathy](#)
- [Cardiovascular Diseases](#)
- [Cell Transformation](#)
- [Central Nervous System Neoplasms](#)
- [Cervical Intraepithelial Neoplasia](#)
- [Cholangiocarcinoma](#)
- [Chromosome Aberrations](#)
- [Chromosome Deletion](#)
- [Cleft Lip](#)
- [Cleft Palate](#)
- [Cocarcinogenesis](#)
- [Colon cancer](#)
- [Colonic Neoplasms](#)
- [Colorectal Neoplasms](#)
- [Cystadenocarcinoma](#)
- [Diabetes Mellitus](#)
- [Diarrhea](#)
- [Disease Progression](#)
- [Disease Susceptibility](#)
- [DNA Damage](#)

- [Drug Eruptions](#)
- [Drug Toxicity](#)
- [Edema](#)
- [Endometrial Neoplasms](#)
- [Endometriosis](#)
- [Esophageal Neoplasms](#)
- [Exanthema](#)
- [Genetic Diseases](#)
- [Genetic Predisposition to Disease](#)
- [Glioblastoma](#)
- [Glioma](#)
- [Head and Neck Neoplasms](#)
- [Hepatitis C](#)
- [HIV Infections](#)
- [Hyperparathyroidism](#)
- [Hypersensitivity](#)
- [Hypopharyngeal Neoplasms](#)
- [Kidney Failure](#)
- [Kidney Neoplasms](#)
- [Liver Diseases](#)
- [Liver Neoplasms](#)
- [Lung carcinoma](#)
- [Lung Neoplasms](#)
- [Lupus Erythematosus](#)
- [Lymphatic Metastasis](#)
- [Mental Disorders](#)

- [Mouth Neoplasms](#)
- [Myoma](#)
- [Nasopharyngeal Neoplasms](#)
- [Neoplasm Invasiveness](#)
- [Neoplasm Metastasis](#)
- [Neoplasm Recurrence](#)
- [Neoplasms](#)
- [Osteosarcoma](#)
- [Otorhinolaryngologic Neoplasms](#)
- [Ovarian cancer](#)
- [Ovarian Neoplasms](#)
- [Pancreatic cancer](#)
- [Pancreatic Neoplasms](#)
- [Papillomavirus Infections](#)
- [Polycystic Kidney](#)
- [Polycystic kidney disease](#)
- [Precancerous Conditions](#)
- [Prostate cancer](#)
- [Prostatic Hyperplasia](#)
- [Prostatic Neoplasms](#)
- [Pulmonary Disease](#)
- [Ras oncogene](#)
- [Rectal Neoplasms](#)
- [Recurrence](#)
- [Skin Neoplasms](#)
- [Small Cell Lung Carcinoma](#)

- [Stomach Neoplasms](#)
- [Thyroid Neoplasms](#)
- [Tongue Neoplasms](#)
- [Tonsillar Neoplasms](#)
- [Urinary Bladder Neoplasms](#)
- [Urinary Calculi](#)
- [Uterine Cervical Neoplasms](#)
- [Uterine Neoplasms](#)
- [Viremia](#)
- [Werner syndrome](#)